抗炎作为对炎症性肠病有前途的治疗剂:系统性审查
Kiarash Ghazvini1,2, Zahra Taghiabadi2, Mohammad Ali Karimi3
1Antimicrobial Resistance Research Center, Department of Microbiology and Virology Faculty of Medicine, Mashhad University of Medical Sciences Mashhad Iran.
概括
抗炎性 (AIPs) 通过减少炎症和恢复肠道健康,显示出治疗性结肠炎和克罗恩病等炎症性肠病 (IBD) 的前景. 需要进一步的研究来改善它们的稳定性和供应以供临床使用.
科学领域:
- 胃肠道学和免疫学
- 类治疗药物 类治疗药物
- 炎症性肠道疾病研究研究
背景情况:
- 炎症性肠病 (IBD) 的发病包括复杂的免疫失调,微生物群失衡和环境触发因素.
- 目前的IBD治疗方法面临局限性,需要新的治疗策略.
- 抗炎 (AIP) 正在成为IBD管理的潜在药物.
研究的目的:
- 系统地审查抗炎 (AIPs) 在治疗性结肠炎和克罗恩病中的疗效.
- 根据最新的科学文献来评估AIP的治疗潜力和局限性.
主要方法:
- 根据PRISMA 2020指南进行了系统审查.
- 2010年至2023年间发表的研究来自Medline,Web of Science和Cochrane数据库.
- 关键词包括IBD,AIP,克罗恩病,性结肠炎和治疗.
主要成果:
- 包括17项研究 (12项动物,4项临床试验,1项病例对照).
- 特定的AIP在抑制炎症 (例如,TNF细胞毒性),恢复肠道平衡,维护肠道屏障完整性方面表现出有效性.
- 其中的例子包括H-SN1,GLP-2二分体,AVX-470,Ac2-26,αs2-素,AMP-18和MBCP.
结论:
- 在IBD模型中,AIP有效降低炎症,调节肠道微生物群,并增强肠道屏障功能.
- 需要解决诸如蛋白酶降解,低生物可用性和潜在细胞毒性等挑战.
- 优化AIP稳定性,输送系统和药理动力学对于临床转换和患者安全至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
600
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
600


